__timestamp | Novartis AG | Xenon Pharmaceuticals Inc. |
---|---|---|
Wednesday, January 1, 2014 | 17345000000 | 5903000 |
Thursday, January 1, 2015 | 17404000000 | 2762000 |
Friday, January 1, 2016 | 17520000000 | 1114000 |
Sunday, January 1, 2017 | 17175000000 | 25573000 |
Monday, January 1, 2018 | 18407000000 | 6000000 |
Tuesday, January 1, 2019 | 14425000000 | 38845000 |
Wednesday, January 1, 2020 | 15121000000 | 50523000 |
Friday, January 1, 2021 | 15867000000 | 75463000 |
Saturday, January 1, 2022 | 15486000000 | 105767000 |
Sunday, January 1, 2023 | 12472000000 | 167512000 |
Monday, January 1, 2024 | 12827000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for strategic planning. This analysis delves into the cost of revenue trends for Novartis AG and Xenon Pharmaceuticals Inc. from 2014 to 2023. Novartis AG, a global healthcare leader, consistently reported a high cost of revenue, peaking in 2018 with a 14% increase from 2017. However, a notable decline of 32% was observed by 2023, reflecting strategic shifts or market challenges. In contrast, Xenon Pharmaceuticals Inc., a smaller player, showed a dramatic rise in cost of revenue, surging over 2800% from 2014 to 2023. This growth trajectory highlights Xenon's expanding operations and market presence. The contrasting trends between these companies underscore the diverse strategies and market dynamics within the pharmaceutical sector.
Cost Insights: Breaking Down AstraZeneca PLC and Xenon Pharmaceuticals Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Novartis AG vs Vertex Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Novartis AG vs Corcept Therapeutics Incorporated
Cost of Revenue Comparison: Novartis AG vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Novartis AG vs Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Novartis AG and Geron Corporation
Cost of Revenue Trends: Novartis AG vs Amphastar Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Xenon Pharmaceuticals Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Xenon Pharmaceuticals Inc. vs Galapagos NV
Comparing Cost of Revenue Efficiency: Xenon Pharmaceuticals Inc. vs Viridian Therapeutics, Inc.